Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use

[1]  Nathan T. Connell.  Ravulizumab: a complementary option for PNH. , 2019, Blood.

[2]  H. Schrezenmeier,et al.  Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. , 2019, Blood.

[3]  R. Wells,et al.  Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. , 2019, Blood.

[4]  K. McKeage.  Ravulizumab: First Global Approval , 2019, Drugs.

[5]  J. Szer,et al.  A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics , 2018, Blood.

[6]  R. Wells,et al.  Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies , 2018, Blood.

[7]  R. Wells,et al.  Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. , 2018, Blood advances.

[8]  Zhao-Xue Yu,et al.  Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.

[9]  M. Borowitz,et al.  ICCS/ESCCA Consensus Guidelines to detect GPI‐deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 1 – Clinical Utility , 2018, Cytometry. Part B, Clinical cytometry.

[10]  T. Kinoshita,et al.  Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.

[11]  F. Şahin,et al.  Pesg PNH diagnosis, follow-up and treatment guidelines. , 2016, American journal of blood research.